Estrella Immunopharma doses first patient in STARLIGHT-1 second cohort for EB103 in NHL

Estrella Immunopharma, Inc.

First patient dosed in second cohort of Phase I/II STARLIGHT-1 trial evaluating EB103 at higher dose.
No dose-limiting toxicities or treatment-related serious adverse events observed in first cohort.
Complete response reported in first cohort; trial targets advanced B-cell non-Hodgkin's lymphomas.
CEO Cheng Liu highlights potential for HIV-associated and CNS lymphoma patients currently excluded from CAR-T.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.